PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY TYPE OF THERAPEUTIC AGENT • Segmentation by therapeutic agent • Comparison by therapeutic agent • Monoclonal antibodies – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Vaccines – Market size and forecast 2017-2022 • Cell and tissue-based therapy – Market size and forecast 2017-2022 • Gene therapy – Market size and forecast 2017-2022 • Market opportunity by therapeutic agent PART 09: MARKET SEGMENTATION BY APPLICATION • Oncology • Autoimmune and inflammatory diseases • Hematology • Others PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Johnson & Johnson • Merck • Pfizer PART 17: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global biologic therapeutics market: Segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Biologics in pipeline 2017-2018 Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global – Market size and forecast 2017-2022 ($ bn) Exhibit 10: Global – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2017 Exhibit 19: Global biologic therapeutics market – Market share by therapeutic agent 2017-2022 (%) Exhibit 20: Comparison by therapeutic agent Exhibit 21: Monoclonal antibodies – Market size and forecast 2017-2022 ($ bn) Exhibit 22: Sales of major monoclonal antibodies 2015-2017 Exhibit 23: Monoclonal antibodies – Year-over-year growth 2018-2022 (%) Exhibit 24: Others – Market size and forecast 2017-2022 ($ bn) Exhibit 25: Others – Year-over-year growth 2018-2022 (%) Exhibit 26: Vaccines – Market size and forecast 2017-2022 ($ bn) Exhibit 27: Vaccines – Year-over-year growth 2018-2022 (%) Exhibit 28: Cell and tissue-based therapy – Market size and forecast 2017-2022 ($ bn) Exhibit 29: Cell and tissue-based therapy – Year-over-year growth 2018-2022 (%) Exhibit 30: Gene therapy– Market size and forecast 2017-2022 ($ bn) Exhibit 31: Gene therapy– Year-over-year growth 2018-2022 (%) Exhibit 32: Market opportunity by type of therapeutic agent Exhibit 33: Sales of biologics used in oncology 2015-2017 ($ millions) Exhibit 34: Customer landscape Exhibit 35: Global biologic therapeutics market – Market share by geography 2017-2022 (%) Exhibit 36: Regional comparison Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 38: Americas – Year-over-year growth 2018-2022 (%) Exhibit 39: Top three countries in Americas Exhibit 40: EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 41: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 42: Top three countries in EMEA Exhibit 43: APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 44: APAC – Year-over-year growth 2018-2022 (%) Exhibit 45: Top three countries in APAC Exhibit 46: Market opportunity Exhibit 47: Treatment costs of some recently approved biologics in US Exhibit 48: Patent expiration dates of some biologics Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: AbbVie overview Exhibit 54: AbbVie – Business segments Exhibit 55: AbbVie – Organizational developments Exhibit 56: AbbVie – Geographic focus Exhibit 57: AbbVie – Key offerings Exhibit 58: Johnson & Johnson overview Exhibit 59: Johnson & Johnson – Business segments Exhibit 60: Johnson & Johnson – Organizational developments Exhibit 61: Johnson & Johnson Geographic focus Exhibit 62: Johnson & Johnson – Segment focus Exhibit 63: Johnson & Johnson – Key offerings Exhibit 64: Merck overview Exhibit 65: Merck – Business segments Exhibit 66: Merck – Organizational developments Exhibit 67: Merck – Geographic focus Exhibit 68: Merck – Segment focus Exhibit 69: Merck – Key offerings Exhibit 70: Pfizer overview Exhibit 71: Pfizer – Business segments Exhibit 72: Pfizer – Organizational developments Exhibit 73: Pfizer – Geographic focus Exhibit 74: Pfizer – Segment focus Exhibit 75: Pfizer – Key offerings    

AbbVie Johnson & Johnson Merck Pfizer